2023年欧洲肿瘤内科学会(European Society for Medical Oncology,ESMO)年会于2023年10月20日~24日在西班牙马德里隆重召开。本次大会报道多项食管癌领域的最新前沿研究。本文将从食管癌围手术期治疗和晚期食管癌药物治疗方面整理并解...2023年欧洲肿瘤内科学会(European Society for Medical Oncology,ESMO)年会于2023年10月20日~24日在西班牙马德里隆重召开。本次大会报道多项食管癌领域的最新前沿研究。本文将从食管癌围手术期治疗和晚期食管癌药物治疗方面整理并解读此次会议中食管癌的重要进展。展开更多
To the editor:Gastrointestinal(GI)cancer is the most common malignancy in China.[1]For many decades,the treatment options for GI cancers have been limited to surgery,radiotherapy,and chemotherapy.Over recent years,imm...To the editor:Gastrointestinal(GI)cancer is the most common malignancy in China.[1]For many decades,the treatment options for GI cancers have been limited to surgery,radiotherapy,and chemotherapy.Over recent years,immune checkpoint inhibitors(ICIs)that target programmed cell death 1(PD-1),or its programmed death-ligand 1(PD-L1),have demonstrated promising efficacies and changed the treatment landscape in GI cancer.[2]However,immune-related adverse events(irAEs)can occur during ICI treatment.Furthermore,ICI-associared cardiotoxicity is a rare but potentially fatal toxic effect.展开更多
文摘2023年欧洲肿瘤内科学会(European Society for Medical Oncology,ESMO)年会于2023年10月20日~24日在西班牙马德里隆重召开。本次大会报道多项食管癌领域的最新前沿研究。本文将从食管癌围手术期治疗和晚期食管癌药物治疗方面整理并解读此次会议中食管癌的重要进展。
文摘To the editor:Gastrointestinal(GI)cancer is the most common malignancy in China.[1]For many decades,the treatment options for GI cancers have been limited to surgery,radiotherapy,and chemotherapy.Over recent years,immune checkpoint inhibitors(ICIs)that target programmed cell death 1(PD-1),or its programmed death-ligand 1(PD-L1),have demonstrated promising efficacies and changed the treatment landscape in GI cancer.[2]However,immune-related adverse events(irAEs)can occur during ICI treatment.Furthermore,ICI-associared cardiotoxicity is a rare but potentially fatal toxic effect.
